Recent studies have evaluated the diagnostic performance of various blood biomarkers, including amyloid-beta (Aβ) and phosphorylated tau (p-Tau), in detecting AD and mild cognitive impairment (MCI). This evidence concerns the gene MAPT and Alzheimer disease.